$ 18.8
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of URGN is 31 and suggests 63% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
